Prognostic value of Lynch syndrome, BRAF^V600E , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.

ABSTRACT:

Background

Current knowledge on prognostic biomarkers (especially BRAF^V600E /RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with proficient mismatch repair (pMMR) tumors. It is uncertain whether these biomarkers have the same prognostic value in mCRC patients with deficient mismatch repair (dMMR) tumors.

Methods

This observational cohort study combined a population-based Dutch cohort (2014-2019) and a large French multicenter cohort (2007-2017). All mCRC patients with a histologically proven dMMR tumor were included.

Results

In our real-world data cohort of 707 dMMR mCRC patients, 438 patients were treated with first-line palliative systemic chemotherapy. Mean age of first-line treated patients was 61.9 years, 49% wer

SUBMITTER: Zwart K 

PROVIDER: S-EPMC10469760 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature